Ads
related to: stage 4 lung cancer survival rate- Identifying Patients
Discover Patient Identification &
IHC Info. Will You Take Action?
- Dosing & Administration
Healthcare Professionals: See How
Your Patients May Receive Treatment
- Access Data & Results
View Data To See If A Treatment For
Metastatic Solid Tumors May Help.
- Official Physician Site
Visit Site For A New Treatment
Option For Metastatic Solid Tumors.
- Mechanism Of Action
MOA For A New Therapy In Multiple
Metastatic Solid Tumor Types.
- Approval Info For HCPs
Explore Eligibility Criteria For A
Therapy For Metastatic Solid Tumors
- Identifying Patients
Search results
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga· 3 days agoWith a median follow-up of approximately three years (34.9 months), adjuvant...4157 (V940) in combination with Keytruda continued to demonstrate a clinically meaningful and durable improvement ...
Lack of insurance may prevent Americans from accessing best cancer drugs
UPI· 3 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. But the drugs,...
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 5 days ago4%), in addition to an improved median progression-free survival (PFS) of 7.06 months (versus 4.8...
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Zacks via Yahoo Finance· 2 days agoAffimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily...
Morningstar· 5 days agoIn 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved
...Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage...
Digital Journal· 3 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Zacks via Yahoo Finance· 3 days agoHowever, last week, the company announced the failure of its late-stage confirmatory TROPiCS-04...
Lack of Insurance Keeps Many Americans From Best Cancer Meds
US News & World Report· 4 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. New policies are needed "to improve health insurance coverage options and to make new treatments ...
...2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid...
Char-Koosta News· 5 days agoMore updated data from the Phase 1 study including in non-small cell lung cancer will be presented...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Zacks via Yahoo Finance· 2 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...